SRP product and index pages do not print CAS, UNII, PubChem CID, molecular formula, sequence, termini, salt form, or a public COA. Identity below is taken only from opened public registries and from primary papers that name Melanotan II / Melanotan-II / MT-II.

One-sentence identity: Melanotan II (MT-II) is a synthetic cyclic lactam heptapeptide analogue of alpha-MSH with the opened PubChem condensed sequence Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-NH2 (CID 92432; CAS 121062-08-6; UNII UPF5CJ93X7; IUPHAR ligand 1323, not approved). It is a non-selective melanocortin agonist (opened IUPHAR: full agonist at human MC1, MC3, MC4, and MC5). It is not alpha-MSH, not Melanotan I / afamelanotide / Scenesse, not PT-141 / bremelanotide / Vyleesi, and not KPV.

Opened SRP product page (16 August 2026): title “Melanotan II (10 mg Vial)”. Category line: Beauty / Skin Research, Research Compounds. Subhead: “Melanotan II 10mg Research Peptide.” Bullets: Vial Size 3ml/10mg; Purity ≥99%; COA available; Made in the USA; lyophilized research peptide; third-party tested; laboratory and research applications only. Description: supplied for controlled laboratory evaluation of Melanotan II within Beauty / Skin Research studies. Research material: Melanotan II. Listed strength: 10 mg Vial. Footer: for laboratory research only; not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application. Price printed $30.00. Availability: “15 in stock (can be backordered).” Shipping-box fields: Weight 1 lbs; Dimensions 1 × .5 × 2 in. Reviews (0). Price, stock, and shipping-box fields are vendor listings, not chemistry.

Not printed on the opened product page and therefore not claimed as SRP-verified: cyclic sequence; free-base vs acetate salt; CAS; UNII; CID; a public COA file; a published 10 mg laboratory dose.

Opened SRP index card (compound-research-guides, 16 August 2026): “Melanotan II (10 mg Vial)” under Other; tag Evidence profile (not “Dedicated evidence guide”); evidence tier Limited human evidence; safety concerns. Overview: “Melanotan II is a synthetic cyclic analogue of alpha-MSH that activates multiple melanocortin receptors.” Mechanism: melanocortin receptor activation can influence pigmentation, appetite, and sexual function; “Its receptor profile is not highly selective.” Evidence: small human studies and case reports exist, but it is not an approved tanning drug and uncontrolled products have been associated with adverse-event concerns. Quality note: “Do not confuse Melanotan II with afamelanotide, a regulated medicine with a different molecule and clinical context.” Last editorial review printed on that index: August 2026.

Opened dedicated-guide URL http://simpleresearchpeptides.com/research-compound-directory/melanotan-ii-research-guide/ returned HTTP 404 on 16 August 2026. This page is written for that missing standalone listing.

Critical identity point. CID 92432 / UNII UPF5CJ93X7 is the C-terminal carboxamide cyclic lactam. Bremelanotide (CID 9941379; InChIKey FFHBJDQSGDNCIV-MFVUMRCOSA-N) is the C-terminal carboxylic acid of the same ring (IUPHAR: “23-carboxylic acid”; King 2007 PMID 17584130: “PT-141, which is the carboxylate derivative of MT-II”). An SRP “Melanotan II 10 mg” lot is not automatically the acetate salt, not bremelanotide, and not afamelanotide. Confirm sequence, C-terminus (amide vs acid), stereochemistry (D-Phe), lactam closure, and salt on a COA / LC-MS.

Registry chaos that must not be collapsed.

• PubChem depositor synonyms include “Melanotan II acetate salt.” That string sits on the free-base CID. It is nomenclature noise, not proof of the SRP counter-ion.
• GSRS validation warns that MELANOTAN II ACETATE UNII WYE6CXB7CH is a potential duplicate. That substance record was not opened. Do not treat WYE6CXB7CH as the SRP lot.
• ClinicalTrials.gov MT-II / MTII is a lexical collision against Type II diabetes, CML, and other “II” strings (opened broad query totalCount 1333). Unused.
• IUPHAR ligand 1323 is MT-II. Ligand 1324 is afamelanotide. Ligand 10408 is bremelanotide. Ligand 1320 is alpha-MSH. Those are four different records.
• MeSH / chemical lists print alpha-MSH CAS 581-05-5 and NDP-MSH CAS 75921-69-6 next to melanotan-II CAS 121062-08-6. Adjacent listing is not identity.

Catalog “Beauty / Skin Research” language does not convert a research cyclic heptapeptide into Scenesse, Vyleesi, endogenous alpha-MSH, or the KPV tripeptide.

The standalone vial is not alpha-MSH. Al-Obeidi 1989 (PMID 2555512) designed cyclic lactam fragments of alpha-MSH4–10 / 4–13. The parent hormone is the 13-residue linear peptide with Met4 and L-Phe7. MT-II replaces Met with Nle, Phe with D-Phe, and closes a 23-membered Asp5–Lys10 lactam.

The standalone vial is not Melanotan I / afamelanotide / Scenesse. Sawyer 1980 (PMID 6777774) made linear [Nle4, D-Phe7]-alpha-MSH (CAS 75921-69-6). That linear 13-mer is the molecule IUPHAR names afamelanotide (ligand 1324; Scenesse; EMA 2014 / FDA 2019). Hadley and Dorr 2006 (PMID 16412534) treat MTI as the linear tanning analogue and MTII as the cyclic truncated peptide. Habbema 2017 (PMID 28266027) states afamelanotide “is the only alpha-MSH analogue that is approved for use in a limited number of medical indications” and that “illegal melanotans are likely risky.” Afamelanotide implant trials (example opened: NCT01097044 CUV030 EPP) are not Melanotan II trials. CT.gov query.intr=afamelanotide returned totalCount 23.

The standalone vial is not PT-141 / bremelanotide / Vyleesi. One atom-level difference: MT-II is the 23-carboxamide; bremelanotide is the 23-carboxylic acid (IUPHAR IUPAC). Formula C50H69N15O9 vs C50H68N14O10. InChIKeys share the stereo suffix MFVUMRCOSA-N but have different first blocks. King 2007 (PMID 17584130) and Hadley and Dorr 2006 (PMID 16412534) describe PT-141 as the Palatin carboxylate analogue that entered human sexual-dysfunction development after MT-II. IUPHAR ligand 10408 is approved: true, FDA 2019. CT.gov query.intr=bremelanotide returned totalCount 10. The opened SRP PT-141 10 mg page is a different SKU.

The standalone vial is not KPV. KPV is three residues (Lys-Pro-Val) at the C-terminus of alpha-MSH. MT-II is a cyclic 4–10 fragment analogue. The opened SRP KPV index card is a Recovery / Inflammation Preclinical evidence entry. Do not cite KPV colitis or keratinocyte papers as Melanotan II evidence.

Do not equate this vial with alpha-MSH, ACTH, Melanotan I, afamelanotide / Scenesse, bremelanotide / PT-141 / Vyleesi, KPV, or SHU9119. Research use only.

Opened primary papers support a non-selective cyclic melanocortin-agonist working model. It is not a treatment claim. It was not generated with an SRP 10 mg vial. Observed means a measurement in an opened paper. Proposed means a hypothesis. Not shown means the opened papers did not establish it for a research-market lot.

SRP index Evidence profile for this SKU: Limited human evidence; safety concerns. That is the house tier. This page does not upgrade it. Label every row. MT-II ≠ alpha-MSH ≠ afamelanotide ≠ PT-141 ≠ KPV. Historical language is not a completed therapeutic program.

Read the “what it did not show” column. Published study designs are historical facts from those papers. They are not a protocol. Historical 1990s study conditions are not instructions for an SRP 10 mg research vial.

Human / NCT snapshot. Historical Arizona pilots = Dorr 1996 n=3 plus Wessells 1998 n=10 and Wessells 2000 n=20. ClinicalTrials.gov: no real MT-II NCT used as efficacy. NCT07437560 is an example record. Distinction-only: NCT01097044 (afamelanotide); NCT03973047, NCT00425256, NCT04179734 (bremelanotide). Do not invent an NCT.

• No human reconstitution, administration, or dosing protocol.
• No claim that this vial is a tanning product, a sexual-function product, a vitiligo therapy, or a sun-protection agent.
• No claim that Melanotan II is afamelanotide, Scenesse, PT-141, bremelanotide, Vyleesi, KPV, or native alpha-MSH.
• No invented CAS, UNII, CID, NCT, or PMID.
• No use of the unopened acetate UNII WYE6CXB7CH as a second peptide.
• No use of TGA or the 2007 consumer-notice HTML as opened sources.
• Case reports of melanoma are listed as case reports. They are not proof of causation.
• NCT07437560 is flagged as an example record. It is not efficacy evidence.
• No FDA-approved therapeutic use of Melanotan II. openFDA melanotan: HTTP 404. IUPHAR 1323: approved false.
• No proof the SRP vial is CID 92432. Sequence, CAS, UNII, salt, and a public COA were not printed.

Each card is a single opened record. Reviews are secondary. Historical study conditions are not instructions. No real MT-II NCT is attached as efficacy. Linear 4-10 PMID 2535874 is distinction only.

Melanotan II is an investigational laboratory research peptide. It is not an FDA-approved drug for human use. This page is educational. It does not provide dosing, reconstitution, administration, or any human-use instructions. The 10 mg mass is a vendor listing, not a published laboratory protocol.

Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.

Laboratory identity is the first practical issue. Opened registries describe Melanotan II as CID 92432 / CAS 121062-08-6 / UNII UPF5CJ93X7 / Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-NH2 / C50H69N15O9. SRP product pages do not print sequence, CAS, UNII, or a public COA. A method written for alpha-MSH, afamelanotide / Scenesse, bremelanotide / PT-141, or KPV is not automatically valid for this vial.

Confirm peptide identity, Asp–Lys lactam cyclization, D-Phe, C-terminal amide (not the bremelanotide acid), stereochemistry, salt, and purity by LC-MS before treating a vial as the literature article. Independently sourced research peptides are not established as equivalent to the Dorr 1996 or Wessells lots. Acetate UNII WYE6CXB7CH was not opened and is not treated as the SRP lot. Historical 1990s study conditions are not a reconstitution scheme.

Opened unlicensed-use literature describes tanning-injection reports and melanoma case reports. Those are reasons for laboratory caution and identity testing, not use instructions. Habbema 2017 states conclusive causal evidence is lacking.

Sources actually opened for the locked draft. Do not add PMIDs or NCTs that are not on the allowed list. NCT07437560 is logged as an example record and is not used as a trial.

Allowed PMID list used on this page: 2555512, 2535874, 6777774, 8637402, 8990120, 9679884, 10493100, 11023702, 11035391, 11101306, 12007532, 16412534, 17584130, 19043625, 19224885, 21564053, 22724573, 28266027. Opened PMC: PMC2587946 (Ryakhovsky); PMC2694735 (King). NCT used as a real trial: none. NCT07437560 logged only as an example record. Distinction NCTs: NCT01097044, NCT03973047, NCT00425256, NCT04179734. Not used: 8986799, 28239848, 24758249, 24784483 (wrong-paper lookups). Hjuler 2014 not confirmed. No other PMIDs were added.

Product links are research materials, not treatment recommendations. Opened SRP Melanotan II page: Melanotan II (10 mg Vial); category Beauty / Skin Research. Footer: for laboratory research only; not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application. Sequence, CAS, UNII, and a public COA were not printed. Do not confuse with alpha-MSH (IUPHAR 1320), afamelanotide / Scenesse (1324), bremelanotide / PT-141 (10408), KPV (Lys-Pro-Val), or the adjacent SRP PT-141 10 mg listing.